Osmind is an electronic health record (EHR) platform designed for mental health clinicians and researchers. Its software supports innovative treatments like ketamine therapy and transcranial magnetic stimulation, while capturing research-grade data. Founded in 2020, Osmind serves over 400 clinics across 45 U.S. states.

Co-founders Lucia Huang and Jimmy Qian bring complementary expertise. Huang previously led operations at neuroscience startup Verge Genomics and was a healthcare investor, while Qian attended medical school at Stanford. In 2022, Osmind raised a $40 million Series B led by DFJ Growth, bringing total funding to $57 million. The company plans to expand its EHR capabilities, grow its 70-person team, and deepen research collaborations. Notably, Osmind published the largest real-world analysis of ketamine therapy for depression with Stanford in March 2022.

Osmind seeks to enable a new era of data-driven "precision psychiatry." Employees have the opportunity to shape an innovative EHR platform during a mental health crisis and contribute to research that advances the field.